---
schema_version: "secwatch.filing_event.v1"
accession: "0001736730-26-000015"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:45:55.363422+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CAMP4 FY2025 net loss $80.4M; cash runway into 2028, GSK deal, SYNGAP1 progress

## Summary
- Net loss of $80.4M in FY2025 vs $51.8M in FY2024, driven by $29.8M non-cash loss on derivative tranche liability.
- Cash and equivalents $109.5M (Dec 31, 2025), up from $64.0M; cash runway extended into 2028.
- GSK collaboration: $17.5M upfront, up to $440M in milestones plus tiered royalties for ASO candidates in neurodegenerative and kidney diseases.
- GLP tox studies for CMP-002 ongoing; global Phase 1/2 trial in SYNGAP1 patients expected as early as H2 2026.
- Paused development of CMP-001 and exploring partnership opportunities for that program.

## SEC filing metadata
- accession: 0001736730-26-000015
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/camp-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001736730-26-000015
- JSON: https://secwatch.observer/filing/0001736730-26-000015.json
- Plain text: https://secwatch.observer/filing/0001736730-26-000015.txt

## Key facts
- Earnings Releases
  Camp4 Therapeutics Corp reported the year ended December 31, 2025 results: net income $80.4 million.
  - Period: the year ended December 31, 2025
  - Net income: $80.4 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2025, was $80.4 million compared to $51.8 million for the year ended December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000173673026000015/0001736730-26-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.